Trial Profile
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line CTX: angiogenic biomarker identification, phase II trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 10 Sep 2018 Status changed from recruiting to discontinued.
- 21 Oct 2015 New trial record